Ascentage Pharma Group International

Yahoo Finance • 19 days ago

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cyclesSt... Full story

Yahoo Finance • 19 days ago

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus patients showed 90% molecular response rate Lo... Full story

Yahoo Finance • 19 days ago

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in patients without T315I m... Full story

Yahoo Finance • 20 days ago

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diagnosed high-risk MDS/CMMLStrong safety p... Full story

Yahoo Finance • 21 days ago

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new treatment option Lis... Full story

Yahoo Finance • 23 days ago

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development a... Full story

Yahoo Finance • last month

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, i... Full story

Yahoo Finance • last month

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025

ROCKVILLE, Md. and SUZHOU, China, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company e... Full story

Yahoo Finance • 2 months ago

Asian Growth Stocks With High Insider Ownership In November 2025

As global markets navigate through a period of heightened scrutiny on AI spending and valuation concerns, the Asian market has shown resilience, with Chinese stocks edging higher amid easing trade tensions. In this environment, growth comp... Full story

Yahoo Finance • 2 months ago

Pinterest downgraded, Tractor Supply upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Evercore ISI upgraded Tractor Supply(T... Full story

Yahoo Finance • 2 months ago

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company e... Full story

Yahoo Finance • 2 months ago

Global Growth Companies With High Insider Ownership October 2025

As global markets navigate a complex landscape marked by lower-than-expected U.S. inflation and fluctuating trade relations, investors are increasingly focusing on growth companies with high insider ownership as potential opportunities. Co... Full story

Yahoo Finance • 2 months ago

Top Asian Growth Companies With Insider Ownership In October 2025

Amidst the backdrop of reignited U.S.-China trade tensions and fluctuating global markets, Asian equities have shown mixed performance, with Japan's stock markets experiencing a notable rise while China's indices displayed modest changes.... Full story

Yahoo Finance • 4 months ago

Form 6K Ascentage Pharma Group Int Ltd For: 21 August

... Full story

Yahoo Finance • 4 months ago

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

Product sales from Olverembatinib in the first half of 2025 increased 93%year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced commercial sales of Lisaftoclax in China, foll... Full story

Yahoo Finance • 4 months ago

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization... Full story

Yahoo Finance • 5 months ago

Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025

ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet m... Full story

Yahoo Finance • 5 months ago

Ascentage Pharma’s Novel Cancer Drug Approved in China

Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best young stocks to buy and hold for 5 years. On July 10, Ascentage Pharma announced that China’s National Medical Products Administration/NMPA approved its novel Bcl-2 sele... Full story

Yahoo Finance • 5 months ago

Ascentage Pharma announces $192.3 million share placement

ROCKVILLE, Md. and SUZHOU, China - Ascentage Pharma Group International Inc. (NASDAQ:AAPG; HKEX:6855), which has seen its stock surge 120% over the past year according to InvestingPro data, announced Monday the pricing of 22 million ordina... Full story

Yahoo Finance • 6 months ago

Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance

By Karen Roman Ascentage Pharma Group International (Nasdaq: AAPG) said it designated Veet Misra, Ph.D., as Chief Financial Officer, and Eric Huang as Senior Vice President of Global Corporate Development and Finance. Dr. Misra has more... Full story